Smith+Nephew (NYSE: SNN) schedules Q2 and H1 2026 results call
Rhea-AI Filing Summary
Smith+Nephew plans to announce its second quarter trading and first half 2026 results for the period ended 27 June 2026 on 4 August 2026 at 7.00am BST / 2.00am EDT. A conference call for financial analysts will follow at 11.30am BST / 6.30am EDT. The company is a global medical technology business with 17,000 employees, operating in around 100 countries, and generated annual sales of $6.2 billion in 2025.
Positive
- None.
Negative
- None.
Key Figures
Annual sales: $6.2 billion
Employees: 17,000
Countries of operation: around 100
+5 more
8 metrics
Annual sales
$6.2 billion
Annual sales generated in 2025
Employees
17,000
Number of employees delivering the company’s mission
Countries of operation
around 100
Number of countries in which the Group operates
Results announcement date
4 August 2026
Planned release date for second quarter trading and first half 2026 results
Results release time (BST)
7.00am BST
Planned time results will be announced
Results release time (EDT)
2.00am EDT
Planned time results will be announced
Analyst call time (BST)
11.30am BST
Scheduled time for the conference call for financial analysts
Analyst call time (EDT)
6.30am EDT
Scheduled time for the conference call for financial analysts
Key Terms
foreign private issuer, forward-looking statements, trading profit margins, reimbursement decisions, +1 more
5 terms
foreign private issuer regulatory
"Form 6-K Report of foreign private issuer pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
forward-looking statements regulatory
"This document may contain forward-looking statements that may or may not prove accurate"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
trading profit margins financial
"statements regarding expected revenue growth and trading profit margins"
reimbursement decisions regulatory
"regulatory approvals, reimbursement decisions or other government actions"
FTSE100 financial
"Smith+Nephew is a constituent of the FTSE100"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
When will Smith+Nephew (SNN) release its second quarter and first half 2026 results?
Smith+Nephew will release its second quarter trading and first half 2026 results on 4 August 2026 at 7.00am BST / 2.00am EDT. The results cover the period ended 27 June 2026 and will be followed by an analyst call.
What time is Smith+Nephew’s (SNN) analyst conference call for the 2026 half-year results?
The conference call for financial analysts is scheduled for 11.30am BST / 6.30am EDT on 4 August 2026. Access details will be published on the Smith+Nephew investor relations website for interested analysts and investors.
What period do Smith+Nephew’s (SNN) upcoming 2026 results cover?
The upcoming announcement will cover second quarter trading and first half 2026 results for the period ended 27 June 2026. This provides an update on performance across Smith+Nephew’s global medical technology operations for the first six months of 2026.
How large is Smith+Nephew (SNN) in terms of sales, employees and global presence?
Smith+Nephew generated $6.2 billion in annual sales in 2025, employs around 17,000 people and operates in around 100 countries. These figures highlight the scale of its global medical technology business across orthopaedics, sports medicine & ENT and advanced wound management.
What is Smith+Nephew’s (SNN) core business focus and purpose?
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. Its stated purpose, called “Life Unlimited”, is to restore people’s bodies and self-belief through medical technologies that improve patients’ lives.
What forward-looking statement cautions does Smith+Nephew (SNN) highlight?
Smith+Nephew notes that forward-looking statements involve risks and uncertainties, citing factors such as geopolitical conflicts, economic conditions, regulatory approvals, product quality issues, litigation, supply chain disruption, foreign exchange volatility and other political, economic, business, competitive or reputational matters that could affect actual results.